FcÎ³R requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.

Leitner, Judith; Egerer, Ricarda; Waidhofer-Söllner, Petra; Grabmeier-Pfistershammer, Katharina; Steinberger, Peter

Leitner, Judith; Egerer, Ricarda; Waidhofer-Söllner, Petra; Grabmeier-Pfistershammer, Katharina; Steinberger, Peter.

Afiliação

Leitner J; Division of Immune Receptors and T Cell Activation, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Egerer R; Division of Immune Receptors and T Cell Activation, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Waidhofer-Söllner P; Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Grabmeier-Pfistershammer K; Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Steinberger P; Division of Immune Receptors and T Cell Activation, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Front Immunol ; 14: 1208631, 2023.

Article em En | MEDLINE | ID: mdl-37575254

Assuntos

Leucócitos Mononucleares; Receptores de IgG; Humanos; Imunoglobulina G

Palavras-chave

41BB; CD137; CD27; Urelumab; Utomilumab; Varlilumab; agonistic antibodies; human T cell costimulation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucócitos Mononucleares / Receptores de IgG Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Áustria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google